Pancreatic carcinoma with mixed differentiation
MONDO:0044727A rare carcinoma with a poor prognosis, characterized by the presence of a mixture of exocrine and neuroendocrine malignant epithelial cells in both the pancreas and metastatic sites. Symptoms include jaundice, abdominal pain, and weight loss.
Also known as: MiNEN of pancreas, mixed exocrine-endocrine carcinoma of the pancreas, pancreatic MiNEN, pancreatic carcinoma with mixed differentiation, pancreatic mixed neuroendocrine-nonneuroendocrine neoplasm, mixed neuroendocrine-nonneuroendocrine neoplasm of pancreas
2874 clinical trials for this condition and its sub-types, 3 tagged with Pancreatic carcinoma with mixed differentiation itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Could a common anesthetic slow pancreatic cancer spread?
Knowledge-focused Recruiting nowThis trial investigates whether a lidocaine infusion given during pancreatic cancer surgery can affect circulating tumor cells (CTCs) — cancer cells that may travel through the blood. Researchers will compare lidocaine to a saline placebo in patients undergoing robotic pancreatec…
Early phase 1 • Sponsor: University of Illinois at Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood test may speed up chemo decisions for deadly pancreatic cancer
Knowledge-focused Recruiting nowThis study is testing whether a blood test that looks for tumor DNA (ctDNA) can tell doctors within weeks if chemotherapy is shrinking a patient's pancreatic cancer. Currently, doctors wait about 8 weeks for a scan to see if treatment is working. The trial will enroll 50 people w…
Phase 2 • Sponsor: University of Miami • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC